Sugi Predict

Sugi Predict / Compounds / SCHEMBL282798

SCHEMBL282798

SCHEMBL282798

OCC[C@H](O)c1cccc(Cl)c1

nearest known ligand 0.56

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
▸ IDO1 P14902 2/20 0.48
▸ ADRB3 P13945 6/20 0.47
▸ ADRB1 P08588 4/20 0.47
▸ ADRB2 P07550 3/20 0.47
▸ SLC2A1 P11166 2/20 0.46
▸ LMNA P02545 1/20 0.44
▸ ACP3 P15309 1/20 0.43
▸ OPRK1 P41145 1/20 0.43
▸ MEN1 O00255 1/20 0.41
▸ KMT2A Q03164 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3156406 1.00 IDO1 (0.48) IDO1ADRB3ADRB1ADRB2SLC2A1
SCHEMBL281883 1.00 IDO1 (0.48) IDO1ADRB3ADRB1ADRB2SLC2A1
SCHEMBL18548557 0.90 ADRB3 (0.46) IDO1ADRB3ADRB1ADRB2SLC2A1
SCHEMBL29493206 0.90 ADRB3 (0.46) IDO1ADRB3ADRB1ADRB2SLC2A1
SCHEMBL3922600 0.86 LMNA (0.46) IDO1ADRB3ADRB1ADRB2SLC2A1
SCHEMBL3146631 0.86 LMNA (0.46) IDO1ADRB3ADRB1ADRB2SLC2A1
SCHEMBL15771267 0.85 ADRB3 (0.44) IDO1ADRB3ADRB1ADRB2SLC2A1
SCHEMBL14692667 0.85 ADRB3 (0.44) IDO1ADRB3ADRB1ADRB2SLC2A1
SCHEMBL14402491 0.85 ADRB1 (0.48) IDO1ADRB3ADRB1ADRB2SLC2A1
SCHEMBL10318241 0.85 ADRB2 (0.44) IDO1ADRB3ADRB1ADRB2SLC2A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 138 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115537405-B Ketoreductase and application thereof in preparation of (S) -1- (3-chlorophenyl) -1, 3-propanediol 尚科生物医药（上海）有限公司 2024-04-12 — — CN claimed
CN-115537405-A Ketoreductase and application thereof in preparation of (S) -1- (3-chlorphenyl) -1, 3-propylene glycol 尚科生物医药（上海）有限公司 2022-12-30 — — CN claimed
CN-114958927-A Method for preparing (S) -1- (3-chlorphenyl) -1, 3-propylene glycol 尚科生物医药（上海）有限公司 2022-08-30 — — CN claimed
CN-119462766-A Liver-targeting nitric oxide donor compound and application thereof 深圳博瑞医药科技有限公司 2025-02-18 — — CN disclosed
CN-115974925-B Thyroid hormone receptor beta agonist and application thereof 烟台药物研究所 2024-10-22 — — CN disclosed
WO-2024183772-A1 CYCLIC PHOSPHATE COMPOUND AS DRUG FOR REGULATING CHOLESTEROL METABOLISM VIA LIVER DELIVERY AND USE 浙江柏拉阿图医药科技有限公司 2024-09-12 — — WO disclosed
CN-118530283-A Cyclic phosphate compound and application thereof 西安新通药物研究股份有限公司 2024-08-23 — — CN disclosed
CN-118401531-A Benzimidazole compound and medical application thereof 中国科学院上海药物研究所 2024-07-26 — — CN disclosed
CN-118290483-A Pyridazinone compound and application thereof 烟台药物研究所 2024-07-05 — — CN disclosed
CN-115537405-B Ketoreductase and application thereof in preparation of (S) -1- (3-chlorophenyl) -1, 3-propanediol 尚科生物医药（上海）有限公司 2024-04-12 — — CN disclosed
CN-115537405-B Ketoreductase and application thereof in preparation of (S) -1- (3-chlorophenyl) -1, 3-propanediol 尚科生物医药（上海）有限公司 2024-04-12 — — CN disclosed
WO-2005051298-A2 NOVEL PHOSPHORUS-CONTAINING THYROMIMETICS METABASIS THERAPEUTICS, INC. (US) 2005-06-09 — — WO disclosed
EP-1532157-A2 NOVEL PHOSPHONIC ACID BASED PRODRUGS OF PMEA AND ITS ANALOGUES Metabasis Therapeutics, Inc. (US) 2005-05-25 — — EP disclosed
EP-1504014-A2 PROCESS FOR PREPARATION OF CYCLIC PRODRUGS OF PMEA AND PMPA Metabasis Therapeutics, Inc. (US) 2005-02-09 — — EP disclosed
US-20040192651-A1 Novel cyclic phosphate diesters of 1,3-propane-1-aryl diols and their use in preparing prodrugs CITIBANK, N.A., AS ADMINISTRATIVE AGENT 2004-09-30 — — US disclosed
WO-2004041834-A2 NOVEL CYCLIC PHOSPHATE DIESTERS OF 1,3-PROPANE-1-ARYL DIOLS AND THEIR USE IN PREPARING PRODRUGS METABASIS THERAPEUTICS, INC. (US) 2004-05-21 — — WO disclosed
WO-2004037161-A2 CYCLIC PRODRUGS OF PMEA ONE OF ITS ANALOGUES METABASIS THERAPEUTICS, INC. (US) 2004-05-06 — — WO disclosed
US-20030229225-A1 Novel phosphonic acid based prodrugs of PMEA and its analogues METABASIS THERAPEUTICS, INC. 2003-12-11 — — US disclosed
US-20030225277-A1 Process for preparation of cyclic prodrugs of PMEA and PMPA METABASIS THERAPEUTICS, INC. 2003-12-04 — — US disclosed
WO-2003095665-A2 PMEA AND PMPA CYCLIC PRODUCING SYNTHESIS METABASIS THERAPEUTICS, INC. (US) 2003-11-20 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030225277-A1 Process for preparation of cyclic prodrugs of PMEA and PMPA MPO, PNP, MAOA IDO1 3416/4885ADRB3 2909/4885ADRB1 2719/4885
US-20030229225-A1 Novel phosphonic acid based prodrugs of PMEA and its analogues MTAP, PNP, MPO IDO1 3603/4885ADRB3 2560/4885ADRB1 3562/4885
US-20040192651-A1 Novel cyclic phosphate diesters of 1,3-propane-1-aryl diols and their use in preparing prodrugs PNP, CYP2S1, CYP2F1 IDO1 1897/4885ADRB3 802/4885ADRB1 846/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.